Stocksigma LogoStocksigma Logo

Epigral Delivers Strong Q2 FY27 Revenue Growth Amid Specialty Expansion

Epigral reported Q2 FY27 revenue growth of 28% YoY to ₹752 Cr, supported by a 6% YoY sales volume increase and improved realizations

Epigral Delivers Strong Q2 FY27 Revenue Growth Amid Specialty Expansion

Epigral Ltd · Investor Presentation · 02 Nov 2026, 7:32 pm

Epigral Delivers Strong Q2 FY27 Revenue Growth Amid Specialty Expansion Epigral reported Q2 FY27 revenue growth of 28% YoY to ₹752 Cr, supported by a 6% YoY sales volume increase and improved realizations. Derivatives & Specialty chemicals contributed 57% of total revenue. EBITDA rose 3% YoY to ₹136 Cr, with margins contracting to 18% due to elevated raw material costs, while PAT grew 26% YoY to ₹64 Cr. For H1 FY27, revenue reached ₹1,461 Cr and PAT stood at ₹164 Cr. Expansions in CPVC and ECH are scheduled for commissioning in Q3 FY27.

Original exchange filing (PDF)

More announcements from Epigral Ltd

All Epigral Ltd announcements